SCHEMBL6879907

SCHEMBL6879907

COC(=O)CCCCCCN(C)C(=O)c1cnc(Nc2c(C)cccc2C)nc1

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 20/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL896466 0.87 HDAC6 (1.00) HDAC6
SCHEMBL15725412 0.87 HDAC6 (0.84) HDAC6
SCHEMBL6878492 0.84 HDAC6 (0.76) HDAC6
SCHEMBL2225590 0.77 HDAC6 (1.00) HDAC6
SCHEMBL15725456 0.77 HDAC6 (0.84) HDAC6
SCHEMBL2224313 0.74 HDAC6 (0.62) HDAC6
SCHEMBL2229659 0.74 HDAC6 (1.00) HDAC6
SCHEMBL15725457 0.74 HDAC6 (0.85) HDAC6
SCHEMBL6877999 0.70 HDAC6 (0.56) HDAC6
SCHEMBL896069 0.70 HDAC6 (1.00) HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200030325-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof ACETYLON PHARMACEUTICALS, INC. 2020-01-30 US disclosed
US-20170305866-A1 Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease THE GENERAL HOSPITAL CORPORATION 2017-10-26 US disclosed
US-20170305866-A1 Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease THE GENERAL HOSPITAL CORPORATION 2017-10-26 US disclosed
US-20160375021-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS, INC. 2016-12-29 US disclosed
US-9512083-B2 Histone deacetylase 6 selective inhibitors for the treatment of bone disease THE GENERAL HOSPITAL CORPORATION (US) 2016-12-06 US disclosed
US-9512083-B2 Histone deacetylase 6 selective inhibitors for the treatment of bone disease THE GENERAL HOSPITAL CORPORATION (US) 2016-12-06 US disclosed
EP-3091004-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF Acetylon Pharmaceuticals, Inc. (US) 2016-11-09 EP disclosed
EP-2526093-B1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS INC (US) 2016-08-17 EP disclosed
US-20150045380-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS 2015-02-12 US disclosed
US-20150045380-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS 2015-02-12 US disclosed
WO-2013013113-A2 HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE THE GENERAL HOSPITAL CORPORATION (US) 2013-01-24 WO disclosed
US-20120190693-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof ACETYLON PHARMACEUTICALS, INC. 2012-07-26 US disclosed
US-20120190693-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof ACETYLON PHARMACEUTICALS, INC. 2012-07-26 US disclosed
US-20120083504-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof ACETYLON PHARMACEUTICALS, INC. 2012-04-05 US disclosed
US-20120083504-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof ACETYLON PHARMACEUTICALS, INC. 2012-04-05 US disclosed
US-8148526-B1 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof ACETYLON PHARMACEUTICALS (US) 2012-04-03 US disclosed
US-8148526-B1 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof ACETYLON PHARMACEUTICALS (US) 2012-04-03 US disclosed
US-20110300134-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS (US) 2011-12-08 US disclosed
US-20110300134-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS (US) 2011-12-08 US disclosed
WO-2011091213-A2 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF ACETYLON PHARMACEUTICALS (US) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300134-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF HDAC6, HDAC1, HDAC3 HDAC6 1/4885
US-20160375021-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF HDAC6, HDAC1, HDAC3 HDAC6 1/4885
US-20150045380-A1 REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF HDAC6, HDAC1, HDAC3 HDAC6 1/4885
US-20200030325-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof HDAC6, HDAC1, HDAC3 HDAC6 1/4885
US-20170305866-A1 Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease HDAC1, HDAC6, HDAC9 HDAC6 2/4885
US-20120190693-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof HDAC6, HDAC1, HDAC3 HDAC6 1/4885
US-20120083504-A1 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof HDAC6, HDAC1, HDAC3 HDAC6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.